Supporting Statement Part A

Medicaid Drug Use Review (DUR) Program

CMS-R-153, OMB 0938-0659

# Background

Section 4401 of the Omnibus Budget Reconciliation Act of 1990 and section 1927(g) of the Social Security Act requires States to provide for a Medicaid Drug Use Review (DUR) program for covered outpatient drugs under fee-for-service (FFS) and managed care organizations (MCOs). The DUR program is required to assure that prescriptions are appropriate, medically necessary, and are not likely to result in adverse medical events. Each State DUR program must consist of prospective drug use review (ProDUR), retrospective drug use review (RetroDUR), data assessment of drug use against predetermined standards, and ongoing educational outreach activities. In addition, States are required to submit an annual DUR program report that includes a description of the nature and scope of State DUR activities as outlined in the statute and regulations.

In this 2021 collection of information request, we revised certain FFS, MCO, and Abbreviated MCO survey questions without making any changes to the survey burden. While a few questions were added to the surveys to address GAO recommendations, aspects of the survey were simplified with grammar updates and formatting edits, resulting in a net burden change of zero.

#

# A. Justification

1. Need and Legal Basis

The authority for requiring States and MCOs to collect data for the DUR program is section 1927(g) of the Social Security Act (the Act), and implementing regulations at 42 CFR 456.700 and 438.3(s).

The information collection requirement is necessary to establish patient profiles in pharmacies, identify problems in prescribing and/or dispensing, determine each program’s ability to meet minimum standards required for Federal financial participation, and ensure quality pharmaceutical care for Medicaid patients.

State Medicaid agencies that have prescription drug programs are required to perform prospective and retrospective DUR in order to identify aberrations in prescribing, dispensing and/or patient behavior.

1. Information Users

States must provide for a review of drug therapy before each prescription is filled or delivered to a Medicaid patient. This review includes screening for potential drug therapy problems due to therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse/misuse. Pharmacists must make a reasonable effort to obtain, record, and maintain Medicaid patient profiles. These profiles must reflect at least the patient’s name, address, telephone number, date of birth/age, gender, history, e.g., allergies, drug reactions, list of medications, and pharmacist’s comments relevant to the individual’s drug therapy.

The State must conduct RetroDUR which provides for the ongoing periodic examination of claims data and other records in order to identify patterns of fraud, abuse, inappropriate or medically unnecessary care. Patterns or trends of drug therapy problems are identified and reviewed to determine the need for intervention activity with pharmacists and/or physicians. States may conduct interventions via telephone, correspondence, or face-to-face contact.

The states and MCOs are provided the reporting instrument (a survey) by CMS, and by responding to the survey, the states generate annual reports which are submitted to CMS for the purposes of monitoring compliance and evaluating the progress of states’ DUR programs. The survey and the annual recordkeeping and reporting requirements under the pertinent regulations, are completed by pharmacists employed by, or contracted with the various state Medicaid programs and their MCOs. The annual reports submitted by states are reviewed and results are compiled by CMS in a format intended to provide information, comparisons and trends related to states’ experiences with DUR. The states benefit from the information and may enhance their programs each year based on state reported innovative practices that are compiled by CMS from the annual reports. A comparison/summary of the data from the annual reports is published on Medicaid.gov annually, and serves as a resource for stakeholders, including but not limited to states, manufacturers, researchers, congress, CMS, the Office of Inspector General (OIG), non-governmental payers and clinicians on the topic of DUR in state Medicaid programs.

1. Use of Information Technology

States are required to submit their annual FFS, MCO, and Abbreviated MCO responses via the CMR-R-153 reporting instrument (a survey) using a CMS-hosted online information technology system called Medicaid Drug Program (MDP). To generate their annual reports, states submit their FFS and MCO responses to the CMS hosted online MDP system.

1. Duplication/Similar Information

CMS is the only Department of Health and Human Services (HHS) component collecting Medicaid DUR data. Therefore, there is no existing initiative which duplicates this data collection that could yield findings in place of DUR data.

1. Small Business

These information collection requirements do not affect small businesses. When processing prescriptions, pharmacies have an automated system that utilizes the prospective data edits to complete the proper filling of the prescription. The pharmacy itself does not collect the data. The data is submitted to the state as the claim is being processed electronically.

1. Less Frequent Collection

RetroDUR activity is required by regulation at least quarterly according to 42 CFR 456.709(a) and State and MCO reports are required to be submitted annually according to 42 CFR 456.712(b) and 438.3(s)(5) by June 30th of each calendar year for the previous Federal Fiscal Year, as determined by the Secretary. Less frequent data collection is not applicable.

1. Special Circumstances

There are no special circumstances that would require an information collection to be conducted in a manner that requires respondents to:

* Report information to the agency more often than quarterly;
* Prepare a written response to a collection of information in fewer than 30 days after receipt of it;
* Submit more than an original and two copies of any document;
* Retain records, other than health, medical, government contract, grant-in-aid, or tax records for more than three years;
* Collect data in connection with a statistical survey that is not designed to produce valid and reliable results that can be generalized to the universe of study,
* Use a statistical data classification that has not been reviewed and approved by OMB;
* Include a pledge of confidentiality that is not supported by authority established in statute or regulation that is not supported by disclosure and data security policies that are consistent with the pledge, or which unnecessarily impedes sharing of data with other agencies for compatible confidential use; or
* Submit proprietary trade secrets, or other confidential information unless the agency can demonstrate that it has instituted procedures to protect the information's confidentiality to the extent permitted by law.
1. Federal Register Notice/Outside Consultation

The 60-day notice published in the Federal Register on September 24, 2021 (86 FR 41047). Comments were received and are attached to this package along with our response. The comments referenced an oversight on the FFS DUR survey. We agree with the comment and updated our Crosswalk-FFS annual Report 2021 Final document and our FFS DUR Survey. The change has no impact on our burden estimates.

The 30-day notice published in the Federal Register on December 10, 2021 (86 FR 70502). Comments are due on/by January 10, 2022.

1. Payments/Gift to Respondents

There are no payments/gifts to respondents.

1. Confidentiality

States are required under 42 CFR 431.300(a) to safeguard recipient protected information. Accordingly, each State maintains a State Plan providing safeguards that restrict the use or disclosure of information concerning applicants and recipients to purposes directly connected with the administration of the plan per Section 1902(a)(7) of the Social Security Act.

1. Sensitive Questions

There are no sensitive questions associated with this collection. Specifically, the collection does not solicit questions of a sensitive nature, such as sexual behavior and attitudes, religious beliefs, and other matters that are commonly considered private.

1. Collection of Information Requirements and Associated Burden Estimates

In accordance with section 1927(g) of the Social Security Act (the Act), and regulations at 42 CFR 456.700, 456.709, 456.711, 456.712, and 438.3(s), states and MCOs are required to collect data for their DUR programs. State Medicaid agencies that have prescription drug programs are required to perform prospective and retrospective DUR in order to identify aberrations in prescribing, dispensing and/or patient behavior. We expect pharmacists employed by, or contracted with the individual states to facilitate the states’ responses. The sub-sections below estimate the associated burden of complying with the statutes and regulations for both FFS programs and MCOs.

*12.1-Wage Estimates*

To derive average costs, we used data from the U.S. Bureau of Labor Statistics’ May 2020 National Occupational Employment and Wage Estimates for all salary estimates [(http://www.bls.gov/oes/current/oes\_nat.htm)](http://www.bls.gov/oes/current/oes_nat.htm). In this regard, the following table presents BLS’ mean hourly wage, our estimated cost of fringe benefits and overhead (calculated at 100 percent of salary), and our adjusted hourly wage.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Occupation Title | Occupation Code | Mean Hourly Wage ($/hr) | Fringe Benefits and Overhead ($/hr) | Adjusted Hourly Wage ($/hr) |
| Pharmacist | 29-1051 | 60.32  | 60.32 | 120.64  |

As indicated, we are adjusting our employee hourly wage estimates by a factor of 100 percent. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly from employer to employer, and because methods of estimating these costs vary widely from study to study. Nonetheless, we believe that doubling the hourly wage to estimate total cost is a reasonably accurate estimation method.

*12.2-PRA-Related Requirements and Associated Burden Estimates*

Claims Data and Other Record Reports Preparation (42 CFR 456.709)

As previously stated above, the pharmacist’s profiling and documentation is primarily an automated function due to the implementation of electronic processing systems. The pharmacist does not produce exception reports. The details of the prescriptions presented to be filled are what create the data that the State gathers and the State or its vendor produces exception reports and drug claims expenditures reporting from this data.

States are required to collect prescription drug utilization data from claims and assess the data against predetermined standards in order to identify potential problems in prescribing and/or dispensing. Data collection involves sorting prescription drug claims data through the use of exception reports. These reports generate specific information on claims using predetermined criteria for exceptions, such as prior authorization and types of drug therapy problems. States generally have their pharmacy point-of-sales vendor produce the exception reports.

Hours: 1,020 hours annually

5 hours per State x 4 responses per year x 51 states.

Cost: $123,053 annually

1,020 hours x $120.64/hr (point of service vendor pharmacist).

Review Claims Data and Other Record Reports & Interventions (42 CFR 456.711)

The DUR Board conducts reviews of the exception reports at their quarterly meetings. As part of the review process, the DUR Board or a specially selected committee determines if intervention is warranted. If intervention is necessary, a pharmacist contractor executes the interventions by form of telephone contact, correspondence, or face-to- face interviews. Interventions are conducted to educate the physician or pharmacist on appropriate prescribing or dispensing practices.

*Review*

Hours: 12,240 hours annually

60 hours x 4 responses per year x 51 Medicaid programs.

Cost: $612,000 annually

12,240 hours x $50/hr (DUR Board members).

DUR board members typically receive a nominal honorarium as represented above. Being a member of the DUR board is looked favorably upon by their employers and the medical community, as they provide their medical expertise for public service.

*Intervention*

Hours: 24,480 hours annually

120 hours x 4 responses per year x 51 Medicaid programs.

Cost: $2,953,267 annually

24,480 hours x $120.64/hr (pharmacist contractor).

Annual Report (42 CFR 456.712 and 438.3)

These sections of the regulation state that the DUR Board and the Medicaid agency are required to report annually to the Medicaid agency and the Secretary, respectively. While the content of the surveys differs marginally, we estimate that the burden for individual states’ combined reports will be identical.

Hours: 3,264 hours

It is estimated that the yearly reporting burden for the surveys is 64 hours per State, making the total burden for 51 Medicaid programs.

Cost: $393,769

3,264 hours x $120.64/hr (pharmacist contractor rate per hour)

*12.3-Burden Summary*

Annual Recordkeeping and Reporting Requirements

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Regulation Under Title 42 of the CFR | Respondents | Responses (per respondent) | Total Responses | Time per Response (hr) | Total Time (hr) | Labor Rate ($/hr) | Capital/ Maintenance Costs ($) | Total Cost ($) |
| 456.709 | 51 | 4 | 204 | 5 | 1,020 | 120.64 | 0 | 123,053 |
| 456.711 | 51 | 4 | 204 | 60 (review) | 12,240 | 50.00 | 0 | 612,000 |
| 4 | 204 | 120 (intervention) | 24,480 | 120.64 | 0 | 2,953,267 |
| 456.712 &438.3 | 51 | 1 | 51 | 64 | 3,264 | 120.64 | 0 | 393,769 |
| TOTAL | 51 | Varies | 663 | Varies | 41,004 | Varies | 0 | 4,082,089 |

When processing prescriptions, pharmacies have an automated system that utilizes the prospective data edits to complete the proper filling of the prescription. The pharmacy itself does not collect the data. The data is submitted to the state as the claim is being processed electronically.

*12.4-Information Collection Instruments and Instruction/Guidance Documents*

States are required to submit their annual survey responses via the CMR-R-153 reporting instrument using a CMS-hosted online information technology system called Medicaid Drug Program (MDP). The DUR State Agency Contact form ensures system access to eligible state representatives. To generate their annual reports, states submit their responses to the FFS, MCO (or MCO Abbreviated) Reports to the CMS hosted online MDP system.

* FFS Annual Report (Revised)
* MCO Annual Report (Revised)
* Abbreviated MCO Report (Revised)
* DUR State Agency Contact form (No Changes)
1. Capital Costs

There are no capital costs.

1. Cost to Federal Government

The federal government pays 50% of the states’ costs, which is $2,041,045.

1. Changes in Burden

In this 2021 collection of information request, we revised certain FFS, MCO, and Abbreviated MCO survey questions without making any changes to the survey burden. While a few questions were added to the surveys to address GAO recommendations, aspects of the survey were simplified with grammar updates and formatting edits, resulting in a net burden change of zero.

1. Publication and Tabulation Dates

CMS plans to post the comparison/summary on Medicaid.gov within six months from the submission due date.

1. Expiration Date

CMS is willing to display the expiration date for OMB approval.

1. Certification Statement

This submission does not contain exceptions to the certification statement.

# B. Collection of Information Employing Statistical Methods

The use of statistical methods does not apply to this collection of information.